secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001493152-24-018898
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow Q1 revenue up 33% to $34.6M; net loss widens; FY2024 guidance at least $180M
--------------------------------------------------------------------------------

- Q1 revenue $34.6M (+33% YoY); GAAP net loss $(13.6M) vs $(6.6M) prior year; adj. EBITDA $0.2M vs $5.3M.
- Reaffirms FY2024 revenue guidance of at least $180M, expecting growth with back half stronger.
- VEVYE covered lives exceed 150M (from 40M); IHEEZO CMS separate reimbursement confirmed retroactive to Jan 1, 2024.
- Signed IHEEZO supply agreements with 7 multi-practice accounts; new patent through 2039. TRIESENCE PPQ batch passing preliminary assays.
- Appointed Greg DiPasquale as SVP, Head of Commercial (from Regeneron). Sold Eton shares for $5.5M cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224018898/0001493152-24-018898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224018898/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer